Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zhendong Chen"'
Autor:
Zhendong Chen, Zishu Wang, Helong Zhang, Ping Yang, Shanzhi Gu, Feng Chen, Zhenyu You, Bo Zhu, Yinying Lu, Feng Bi, Zhenggang Ren, Xi Chen, Zhendong Zheng, Xiaoli Xin, Junhui Chen, Aibing Xu, Jieer Ying, Xiaoyu Wen, Chengxu Cui, Liqing Wu, Jinlu Shan, Yuxian Bai, Hongming Pan, Jufeng Wang, Jian Wu, Li Xu, Zhiqiang Meng, Meng Qiu, Xiufeng Liu, Shukui Qin
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 39(27)
PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative, has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study compared the efficacy and safety of donafenib versus sorafenib as first-l
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundEmerging clinical data suggest that an immune checkpoint inhibitor in combination with an antiangiogenic agent is a reasonable strategy for multiple malignancies. We assessed the combination of camrelizumab with apatinib in pretreated advan
Publikováno v:
Journal of Cancer Research and Therapeutics, Vol 15, Iss 2, Pp 365-369 (2019)
Aim: We aimed to evaluate the efficacy and safety of apatinib treatment and its impact on the quality of life (QOL) of patients with advanced gastric cancer (GC) who experienced failure with at least two chemotherapeutic regimens. Materials and Metho
Autor:
Jessie Zou, Yoon-Koo Kang, Jiwei Liu, Chao Jung Tsao, Ann-Lii Cheng, Jun Suk Kim, Karin Burock, Jiejun Wang, Houjie Liang, Rongcheng Luo, Jianming Xu, Shukui Qin, Zhongzhen Guan, Jifeng Feng, Yan Sun, D. Voliotis, Sheng-Long Ye, Hongming Pan, Tsai Sheng Yang, Zhendong Chen, Won Young Tak
Publikováno v:
The Lancet Oncology. 10:25-34
Summary Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and safety of new therapeutic options in an Asia-Pacific popul
Autor:
Chao Jung Tsao, Giuseppe Lentini, Shukui Qin, Jun Suk Kim, Fang Fang, Zhongzhen Guan, D. Voliotis, Jessie Zou, Yoon-Koo Kang, Ann-Lii Cheng, Jianming Xu, Shiying Yu, Tsai Sheng Yang, Zhendong Chen, Hongming Pan, Won Young Tak
Publikováno v:
European journal of cancer (Oxford, England : 1990). 48(10)
Background The phase III Sorafenib Asia–Pacific (AP) trial—conducted in China, Taiwan and South Korea – confirmed that sorafenib improves overall survival (OS) and is safe for patients with advanced hepatocellular carcinoma (HCC). We performed